No Data
No Data
Appili Therapeutics Brief: Adds New Subject Matter Listed in the U.S. Food and Drug Administration's Orange Book
Appili Therapeutics Brief: Says New Patents "Provide Additional Composition of Matter and Methods of Use Claims, Strengthening Protection For Liquid Oral Taste-masked Reformulation"
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Express News | Appili Therapeutics Inc - Four New Funding Proposals, Totalling US$117.5 Mln, Submitted for Review
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update